Health Condition 1: M638- Disorders of muscle in diseases classified elsewhere
Conditions
Interventions
Intervention1: Standard of care with beta-1,3-1,6-Glucan: It has been proven to have the potent anti-inflammatory properties.Dose:Food Supplement Administration, once in oral route.
Control Interventi
Sponsors
Muthulakshmikadalraja Charitable Trust
Eligibility
Inclusion criteria
Inclusion criteria: 1.Subject who diagnosed with another muscular dystrophy other than Limb-girdle Muscular Dystrophy (LGMD) 2.Male and Female subjects of age in between 3 years to 70 years 3.Subjects and legally authorized representative for vulnerable subjects must be willing to participate in the study and provide a written informed consent 4.Subject willing to and able to comply with the protocol
Exclusion criteria
Exclusion criteria: 1.Subject participated in another clinical trial in the last 30 days. 2.Subjects and legally authorized representative for vulnerable subjects who has not given informed consent for this study 3.Subjects with history of multiple sclerosis 4.Subjects with history of any muscular atrophy 5.Pregnant and lactating females
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Observation of changes in the levels of IL-6 and Myoglobin urea from the baseline.Timepoint: 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Measurement of the levels of CK, Titin, TNF, Haptoglobin, Dystrophin level, LFT, CBC, Cystatin C 2.Immunological Parameters: IL-13, CD-40, ESR 3.Muscle function assessments Timepoint: Day 30 3,Day 60 3,Day 90 3,Day 120 3,Day 180 3 and Monitoring Adverse events each visits | — |
Countries
India
Contacts
Public ContactDr Raghavan Kadalraja
RK Maples Hospital
Outcome results
None listed